Interventions
MCI, peripheral arterial disease, dementia, ischemic stroke
MAY, SECONDARY, PERIPHERAL ARTERIAL DISEASE, ISCHEMIC STROKE
Between May 25, 2015, and March 31, 2018, participants were treated for up to 96 weeks with 1 placebo tablet twice daily or 1 cilostazol tablet, 50 mg twice daily; in Japan, the approved cilostazol dosage for peripheral arterial disease and ischemic stroke is 200 mg daily. Dose reduction during the treatment protocol was not allowed. Cilostazol and the placebo were provided by Otsuka Pharmaceutical Co, Ltd.The intervention ceased when patients were diagnosed with dementia because the secondary end points included the conversion to dementia. In Japan, cholinesterase inhibitors and memantine have been widely administered to patients with dementia but not approved for those with MCI. To minimize the effects of these antidementia drugs on evaluation of cognitive function after conversion to dementia, conversion was included as a criterion for discontinuation.